Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Multiple near-term clinical data readouts (WVE-007 Phase 1 600mg SAD and WVE-006 600mg cohort) expected in Q4 2026, plus a planned maintenance-trial initiation and CTA filing, create a catalyst-dense window with binary risk skewed by the March 2026 obesity-data disappointment.
Wave confirmed it expects to share data from the Phase 1 600 mg single-ascending-dose cohort of WVE-007 in Q4 2026. Given the sharp negative market reaction to the March 2026 higher-dose obesity data, this readout is a binary catalyst that could either restore confidence in the dose-response profile or reinforce safety/efficacy concerns.
Wave Life Sciences Press ReleaseWave is on track to report data from the 600 mg monthly multidose cohort of WVE-006 in AATD during Q4 2026. Positive data would support the FDA-aligned registrational/accelerated-approval pathway and could drive upside; disappointing data would pressure shares.
Wave Life Sciences Press ReleaseWave remains on track to initiate a clinical trial of WVE-007 as a maintenance therapy to preserve weight loss after incretin discontinuation in Q4 2026. A timely initiation would reinforce the obesity franchise narrative and could be modestly positive.
Wave Life Sciences Press ReleaseWave expects to file a clinical trial application for WVE-008 (PNPLA3 liver disease RNA editing) in Q4 2026. A timely CTA filing would demonstrate pipeline progression and could provide a modest positive catalyst.
Wave Life Sciences Press ReleaseWave reported Q3 2026 revenue of $13.2M (up from $7.6M), net loss of $61.9M, and cash of $431.0M with runway into Q3 2028, plus a $12M GSK milestone due in Q4. The solid balance sheet reduces near-term financing risk, a supportive factor for sentiment.
Wave Life Sciences Press ReleaseIn October 2026 Wave announced FDA alignment on a two-year registrational trial with a one-year interim analysis supporting potential accelerated approval based on AATD biomarkers, and FDA support for its LC-MS assay. This de-risks the regulatory path and remains an ongoing positive overhang into the Q4 data readout.
Wave Life Sciences Press ReleaseIn March 2026 WVE-007 400 mg showed only ~5% visceral fat reduction at three months, sending shares down over 55% in a single session. This remains a sentiment overhang that raises the stakes for the upcoming Q4 WVE-007 readouts, though some analysts called the reaction overdone.
Reuters